Kiniksa Pharmaceuticals International Plc.'s net tangible assets is $650M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), KNSA shows a net tangible assets of $650M. That compares with $500M in the prior-year period — up 32.1% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, KNSA's net tangible assets is now $650M (was $500M) — a 32.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Kiniksa Pharmaceuticals International Plc. is outperforming or lagging.
Tracking KNSA's net tangible assets over time shows whether Kiniksa Pharmaceuticals International Plc. is scaling, shrinking, or reshaping that part of the business. The current reading is $650M That compares with $500M in the prior-year period — up 32.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this net tangible assets page, Stockcircle has Kiniksa Pharmaceuticals International Plc.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $650M) with ownership activity and broader fundamentals.
Kiniksa Pharmaceuticals International Plc.'s net tangible assets is $650M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.